A Failed Trial, A Future Clue: The BOLD Study for Biliary Atresia

PARIS, FRANCE – July 24, 2026 – In the world of rare disease research, hope is a powerful but fragile currency. This week, that fragility was felt acutely by thousands of families worldwide when Ipsen, a global biopharmaceutical company, announced that its landmark Phase III BOLD trial did not meet its primary goal. The study evaluated whether the drug Bylvay (odevixibat) could improve native liver survival in infants with biliary atresia, a devastating liver disease with no approved medical treatment. The outcome was a profound disappointment, yet it is far from the end of the story. In the complex landscape of medical innovation, even a failure can become a critical signpost, pointing the way toward future breakthroughs.

The Weight of Waiting

To understand the weight of this news, one must first understand biliary atresia (BA). It is a rare and ruthless condition, affecting roughly one in every 10,000 to 20,000 newborns. For reasons not fully understood, the bile ducts inside and outside the liver become blocked or destroyed shortly after birth. Bile, essential for digestion, builds up in the liver, causing progressive and irreversible damage. The first line of defense is a surgical procedure called the Kasai hepatoportoenterostomy (HPE), which attempts to restore bile flow. While it can be life-saving, it is not a cure. For most children, the Kasai procedure is a bridge, buying precious time until the inevitable next step: a liver transplant.

Biliary atresia is the number one cause of liver transplantation in children, often before they reach their second birthday. This reality places an immense burden on patients and their families, who navigate a world of constant medical vigilance, specialized diets, and the agonizing wait for a donor organ. The BOLD trial represented a beacon of hope—the first global Phase III study aimed at modifying the course of the disease itself, potentially delaying or even preventing the need for a transplant.

“This outcome is disappointing for patients living with this serious disease and their families,” stated Christelle Huguet, PhD, EVP Head of R&D at Ipsen, in the company’s announcement. Lead investigator Dr. Saul J. Karpen, a pediatric hepatologist at Virginia Commonwealth University, echoed the sentiment, noting that the community is left with “very few therapeutic options.” For the families who participated, this result closes one door on a long-awaited medical intervention.

A Question of Mechanism

The scientific rationale for testing Bylvay in biliary atresia was sound. The drug is an ileal bile acid transport (IBAT) inhibitor, designed to block the reabsorption of bile acids in the intestine, forcing them to be excreted from the body. This lowers the overall concentration of toxic bile acids that damage the liver. The approach has proven successful, leading to Bylvay’s approval for treating severe itching caused by bile acid buildup in other rare cholestatic conditions, namely Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

So, why did it fail in biliary atresia? The answer may lie in the fundamental pathology of the disease. In BA, the primary problem is a physical blockage or absence of bile ducts. If bile cannot effectively drain from the liver into the intestine in the first place, a drug that works downstream in the intestine to prevent reabsorption may have a limited impact on the initial hepatic injury. This underscores a crucial lesson in rare disease drug development: despite sharing common symptoms like cholestasis, each disease has a unique biological fingerprint that may not respond to the same therapeutic key. The challenge in BA is not just managing bile acids, but addressing the underlying inflammatory and fibrotic processes that destroy the ducts. This same hurdle was encountered by another IBAT inhibitor, maralixibat, which also failed to meet its endpoint in a BA trial, suggesting the target itself may be insufficient for this specific disease.

Mining the Data for a New Direction

While the headline reads as a failure, the true legacy of the BOLD trial will be written in the data it leaves behind. As the largest and most comprehensive study ever conducted in biliary atresia, enrolling 254 patients across 19 countries, it has created an unparalleled repository of biological information. “As the first global Phase III trial in biliary atresia, BOLD has generated the most comprehensive dataset ever assembled in this disease,” Dr. Karpen noted. He emphasized that the commitment of the participating children and families has “produced valuable insights that will deepen our understanding of biliary atresia and provide a crucial basis for future research.”

This is where the tangible difference emerges from the disappointment. Biliary atresia is known to be a heterogeneous disease, meaning it presents and progresses differently among patients. Researchers can now meticulously analyze the BOLD dataset for clues. They will look for patterns and biomarkers, asking critical questions: Did certain subgroups of patients show any response? Can we identify genetic markers or early clinical signs that predict disease severity? Answering these questions could pave the way for more targeted therapies, moving from a one-size-fits-all approach to precision medicine.

Ipsen has confirmed that an open-label extension study, BOLD-EXT, is ongoing, which will continue to provide long-term data. The full dataset from the main trial will become a foundational resource for the entire scientific community, helping to design smarter, more targeted trials in the future. This is the often-unseen value of a well-run but negative trial: it advances the science by illuminating what doesn’t work and, more importantly, providing the tools to discover what might.

Resilience in the Face of R&D Risk

For Ipsen, the result is undoubtedly a strategic setback but not a crippling blow. The company has built a diversified portfolio, and its Rare Disease franchise remains strong, bolstered by Bylvay's existing approvals in PFIC and ALGS and the performance of other drugs. Recent successes, like the European conditional approval for Ojemda® in a type of pediatric brain tumor, demonstrate the company's broader R&D momentum. Investors appeared to take the news in stride, recognizing that high-risk, high-reward ventures in rare pediatric diseases are fraught with uncertainty.

The BOLD trial's outcome serves as a sober reminder of the immense difficulty and cost of developing drugs for small, vulnerable populations. Yet, it also highlights the resilience required of companies willing to take on these challenges. By investing in the largest-ever trial for biliary atresia, Ipsen has moved the entire field forward. The path to a medical treatment for this devastating disease remains long and uncertain, but the map is now clearer than it was before. The families and researchers pressing on now have a richer, more detailed understanding of the territory ahead, thanks to the children and investigators who embarked on this bold journey.